Pulse Biosciences, Inc. (PLSE) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Pulse Biosciences is a development-stage medical device company focused on its proprietary Nano-pulse Stimulation (NPS) technology. The company has shifted its primary focus from dermatology to cardiology (specifically atrial fibrillation) and soft tissue ablation. It currently generates no revenue and relies on equity financing to fund operations.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenues | $0 | $0 |
| Net Loss | $(16.8) million | $(10.1) million |
| Net Loss Per Share (Basic & Diluted) | $(0.25) | $(0.18) |
| Operating Expenses | $18.0 million | $10.6 million |
| Research & Development | $10.3 million | $6.7 million |
| General & Administrative | $7.7 million | $3.9 million |
| Stock-Based Compensation | $5.7 million | $1.8 million |
| Cash and Cash Equivalents (End of Period) | $119.3 million | $34.9 million |
| Net Cash Used in Operating Activities | $(13.5) million | $(9.8) million |
| Net Cash Provided by Financing Activities | $14.8 million | $0.3 million |
| Total Liabilities | $14.9 million | $17.6 million |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by $6.7 million (66%) compared to Q1 2024, driven primarily by higher operating expenses.
- Expense Growth: R&D expenses rose $3.6 million and G&A expenses rose $3.9 million. Significant contributors to this increase were stock-based compensation (up $3.9 million) and increased compensation/employee-related costs.
- Financing Activity: Financing cash flow surged to $14.8 million, primarily due to $14.1 million in proceeds from the exercise of warrants related to the 2024 Rights Offering. In contrast, Q1 2024 saw minimal financing activity.
- Liquidity Position: Cash balances increased significantly from $34.9 million in Q1 2024 to $119.3 million in Q1 2025, bolstered by the warrant exercises and interest income ($1.2 million vs $0.5 million).
- Inventory: The company began capitalizing inventory ($30,000) in Q1 2025 in preparation for early pilot commercialization of its percutaneous electrodes, whereas no inventory was held in the prior period.
Outlook, Management Commentary, and Risks
- Product Pipeline:
- Soft Tissue: Received FDA 510(k) clearance for the nsPFA Percutaneous Electrode System. Currently in a pilot program with 8 sites and over 90 procedures completed. A clinical trial for benign thyroid nodules is expected to commence in mid-2025.
- Cardiac Surgery: Received FDA Breakthrough Device Designation for the nsPFA Cardiac Surgery System. A pivotal clinical trial for atrial fibrillation (AF) is expected to begin in mid-2025.
- Cardiac Catheter: The nsPFA 360° Cardiac Catheter study has enrolled 100 patients. A U.S. IDE pivotal clinical study is expected to commence in mid-2025.
- Capital Requirements: Management believes current cash resources ($119.3 million) are sufficient to fund operations for at least the next 12 months. However, the company explicitly states it will need to raise additional capital in the future to fully develop and commercialize its products.
- Stock-Based Compensation: The company issued new executive stock options with market-based and performance-based vesting conditions. As of March 31, 2025, management determined it was not probable that the performance conditions would be achieved, so no expense was booked for these specific grants yet.
- Risks:
- Financing Risk: No assurance that additional financing will be available on acceptable terms. Failure to raise capital could force the company to curtail operations, reduce headcount, or delist.
- Regulatory Risk: Future products require PMA approval or 510(k) clearance. Delays or denials by the FDA would materially harm the business.
- Concentration Risk: Co-Chairman Robert W. Duggan owns approximately 72% of the voting power, limiting minority shareholder influence.
- Profitability: The company has incurred losses since inception and expects to continue incurring losses for the foreseeable future.
Investor Verification Checklist
- Verify the timeline and enrollment status of the pivotal clinical trials for the Cardiac Clamp and 360° Catheter scheduled for mid-2025.
- Monitor the company's cash burn rate against the $119.3 million cash balance to assess the runway for future financing needs.
- Review the terms of the 2024 Rights Offering warrants, specifically the redemption features (150% and 200% VWAP triggers) and the remaining outstanding warrants (208,744).
- Assess the progress of the pilot commercialization program for the Percutaneous Electrode System and the transition to a full clinical trial for thyroid nodules.
- Track the probability assessment of the performance-based stock options granted to executives, as changes in this assessment could materially impact future stock-based compensation expenses.